Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 101 to 150 of 344

Type: Guidance`Remove $Type: Guidance filter`

Guidance and quality standards awaiting development
Title	Type
Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids	HealthTech guidance
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Excimer Laser Trabeculotomy (ELT) for glaucoma	HealthTech guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]	Technology appraisal guidance
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]	Technology appraisal guidance
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]	Technology appraisal guidance
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]	Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies	HealthTech guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]	Technology appraisal guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]	Technology appraisal guidance
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]	Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ianalumab for treating active Sjogren's syndrome [ID6634]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
ID6611 Obesity, overweight - semaglutide (including review of TA875)	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance
Iptacopan for treating primary IgA nephropathy [ID6640]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]	Technology appraisal guidance
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication	HealthTech guidance

Results per page

10
25
50
All